BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17602083)

  • 1. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma.
    Ito N; Eto M; Nakamura E; Takahashi A; Tsukamoto T; Toma H; Nakazawa H; Hirao Y; Uemura H; Kagawa S; Kanayama H; Nose Y; Kinukawa N; Nakamura T; Jinnai N; Seki T; Takamatsu M; Masui Y; Naito S; Ogawa O
    J Clin Oncol; 2007 Jul; 25(19):2785-91. PubMed ID: 17602083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma.
    Eto M; Kamba T; Miyake H; Fujisawa M; Kamai T; Uemura H; Tsukamoto T; Azuma H; Matsubara A; Nishimura K; Nakamura T; Ogawa O; Naito S;
    Eur Urol; 2013 Apr; 63(4):745-52. PubMed ID: 23063454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Single Nucleotide Polymorphisms in STAT3 with Hand-Foot Skin Reactions in Patients with Metastatic Renal Cell Carcinoma Treated with Multiple Tyrosine Kinase Inhibitors: A Retrospective Analysis in Japanese Patients.
    Yamamoto K; Shinomiya K; Ioroi T; Hirata S; Harada K; Suno M; Nishioka T; Kume M; Makimoto H; Nakagawa T; Hirano T; Bito T; Nishigori C; Miyake H; Fujisawa M; Hirai M
    Target Oncol; 2016 Feb; 11(1):93-9. PubMed ID: 26300443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low expression of microphthalmia-associated transcription factor, a potential molecular target for interferon-alpha susceptibility, is associated with metastasis in renal cell carcinoma.
    Shimazui T; Kojima T; Yoshikawa K; Ami Y; Oikawa T; Uchida K; Akaza H
    Cancer Sci; 2009 Sep; 100(9):1714-8. PubMed ID: 19496784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
    Donskov F
    Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon in metastatic renal cell carcinoma.
    Fosså SD
    Semin Oncol; 2000 Apr; 27(2):187-93. PubMed ID: 10768597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronically administered immunotherapy with low-dose IL-2 and IFN-alpha in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile.
    Vaglio A; Alberici F; Maggiore U; Buti S; Potenzoni D; Passalacqua R; Buzio C
    Oncology; 2009; 76(1):69-76. PubMed ID: 19047813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of metastatic renal cell carcinoma.
    Reeves DJ; Liu CY
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
    Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.
    Kawano Y; Takahashi W; Eto M; Kamba T; Miyake H; Fujisawa M; Kamai T; Uemura H; Tsukamoto T; Azuma H; Matsubara A; Nishimura K; Nakamura T; Ogawa O; Naito S
    Cancer Sci; 2016 Jul; 107(7):1013-7. PubMed ID: 27089226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective Jak-Stat activation in renal cell carcinoma is associated with interferon-alpha resistance.
    Shang D; Liu Y; Ito N; Kamoto T; Ogawa O
    Cancer Sci; 2007 Aug; 98(8):1259-64. PubMed ID: 17573897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon-alpha resistance associated genes in renal cell carcinoma identified by expression profiling.
    Korkola JE; Kondagunta GV; Reuter VE; Motzer RJ; Chaganti RS
    J Urol; 2007 Apr; 177(4):1264-8; discussion 1268. PubMed ID: 17382702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT3 polymorphism rs4796793 may be a predictive factor of tumor response to multiple tyrosine kinase inhibitors in metastatic renal cell carcinoma in Japanese population.
    Yamamoto K; Ioroi T; Kanaya K; Shinomiya K; Komoto S; Hirata S; Harada K; Watanabe A; Suno M; Nishioka T; Kume M; Makimoto H; Nakagawa T; Hirano T; Miyake H; Fujisawa M; Hirai M
    Med Oncol; 2016 Mar; 33(3):24. PubMed ID: 26833481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study.
    King JK; Yeh SH; Lin MW; Liu CJ; Lai MY; Kao JH; Chen DS; Chen PJ
    Hepatology; 2002 Dec; 36(6):1416-24. PubMed ID: 12447867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential profiling analysis of proteins involved in anti-proliferative effect of interferon-alpha on renal cell carcinoma cell lines by protein biochip technology.
    Nakamura K; Yoshikawa K; Yamada Y; Saga S; Aoki S; Taki T; Tobiume M; Shimazui T; Akaza H; Honda N
    Int J Oncol; 2006 Apr; 28(4):965-70. PubMed ID: 16525647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of interferon alpha therapy for advanced renal cell carcinoma. Fukushima Renal Cancer Study Group].
    Ogihara M; Aikawa K; Suzuki T; Yanagida T; Kushida N; Yamaguchi O; Shiraiwa Y; Kumakawa K; Koseki K; Ichijo S; Date T; Kurosu S; Takeuchi M; Yokoyama J; Murakami F; Itoh K; Noguchi M
    Gan To Kagaku Ryoho; 2000 Sep; 27(10):1533-9. PubMed ID: 11015998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma.
    Kleinrath T; Gassner C; Lackner P; Thurnher M; Ramoner R
    J Clin Oncol; 2007 Mar; 25(7):845-51. PubMed ID: 17327605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The sensitivity of renal cell carcinoma cells to interferon alpha correlates with p53-induction and involves Bax.
    Wittnebel S; Jalil A; Thiery J; DaRocha S; Viey E; Escudier B; Chouaib S; Caignard A
    Eur Cytokine Netw; 2005 Jun; 16(2):123-7. PubMed ID: 15941683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of interferon-alpha A/D in combination with the Japanese and Chinese traditional herbal medicine juzen-taiho-to on lung metastasis of murine renal cell carcinoma.
    Muraishi Y; Mitani N; Yamaura T; Fuse H; Saiki I
    Anticancer Res; 2000; 20(5A):2931-7. PubMed ID: 11062703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.